Kineta (KANT)announced at the Society for Immunotherapy in Cancer in Houston, TX an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, an anti-VISTA monoclonal antibody, as ...

Lupin has received tentative approval from the Food and Drug Administration for raltegravir tablets, 600 mg, which is a ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti ...

Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at $1.9 per share, versus a year-ago loss of $9.53 per share. Moderna projects to report revenue of $1.25 billion ...

ASHG welcomed eight 2024–2026 Human Genetics Scholars who are recognized for their accomplishments and commitment to fostering DEI in human genetics and genomics.

SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer ...

The fresh inflation print is seen as crucial in judging whether the European Central Bank could consider a ...

The 11th Edition of Merck Foundation Africa Asia Luminary was officially inaugurated by The President of the United Republic of Tanzania, H.E. Dr. SAMIA SULUHU HASSAN, Chairman of Merck Foundation ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

A key panel of U.S. health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc. and Merck & Co. that protect against pneumococcal disease, clearing a path ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...